VERV Overview

Eli Lilly Acquires Verve Therapeutics: Eli Lilly and Company has successfully completed its acquisition of Verve Therapeutics, a Boston-based company focused on developing genetic medicines for cardiovascular disease, aiming to transform treatment options for patients worldwide.

Commitment to Innovation: Lilly emphasizes its dedication to advancing healthcare through innovative research in various fields, including cardiometabolic health, while also addressing the importance of diversity in clinical trials and ensuring medicine accessibility.

Eli Lilly and Company: The company is recognized for its contributions to the pharmaceutical industry, particularly in developing innovative treatments.

Verve Therapeutics, Inc.: This company is highlighted for its advancements in gene editing technologies aimed at addressing genetic diseases.

Hasbro Options Activity: Hasbro, Inc. (HAS) has seen a significant options volume of 19,352 contracts today, with a notable focus on the $82.50 strike call option expiring September 19, 2025, which accounted for 5,210 contracts.

Verve Therapeutics Options Activity: Verve Therapeutics Inc. (VERV) reported an options volume of 23,144 contracts, highlighting strong interest in the $10 strike call option expiring November 21, 2025, with 8,304 contracts traded.

NASDAQ 100 After Hours Performance: The NASDAQ 100 is up 104.25 points to 23,266.66 with a total after-hours volume of 148,678,166 shares traded. Notable stocks include Direxion Daily TSLA Bull 2X Shares down slightly, Intel Corporation preparing for an earnings report, and Alphabet Inc. receiving positive revisions in earnings forecasts.

Stock Highlights: Key active stocks include NVIDIA Corporation and UiPath, both showing slight increases, while Chipotle Mexican Grill and Rocket Companies experienced declines. Current price performances indicate various stocks are near or above their target prices, reflecting mixed investor sentiment.

Impact of Tariff Announcement: President Donald Trump's announcement of a potential 200% tariff on imported pharmaceuticals has created mixed reactions, with investors showing cautious optimism despite a broader stock market decline.

Pharmaceutical Index Performance: The NYSE Arca Pharmaceutical Index has seen a 1% increase over the past week, contrasting with the flat performance of the S&P 500 during the same period.

Investigation of Companies: Halper Sadeh LLC is investigating Verve Therapeutics, Cantaloupe, and Sage Therapeutics for potential violations of federal securities laws related to their sales to Eli Lilly, 365 Retail Markets, and Supernus Pharmaceuticals, respectively.

Shareholder Rights: The law firm encourages shareholders from these companies to contact them for information on their legal rights and options regarding the proposed transactions, with no upfront legal fees required.